Appendix 4E and 2022 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Full Year Results and Investor Conference Call Details
- Q4 2022 Business update to accompany quarterly results
- Appendix 4C and Activities Report - December 2022 Quarter
- Webcast link correction - JP Morgan Conference Presentation
- ZIRCON Ph III Renal Cancer Study to be Presented at ASCO GU
Later from Telix Pharmaceuticals
- 2022 Full Year Results Presentation
- FDA approval of expanded indication of Illuccix in the US
- Illuccix European Marketing Authorisation Application Update
- Telix Preclinical Development of Radiolabelled Olaratumab
- Appendix 4C and Activities Report - March 2023 Quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals